% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Apostolidis:179574,
author = {L. Apostolidis and K. Lang and L. Sisic and E. Busch and A.
Ahadova$^*$ and R. Wullenkord and H. Nienhüser and A.
Billeter and B. Müller-Stich and M. Kloor$^*$ and D.
Jaeger$^*$ and G. M. Haag$^*$},
title = {{O}utcome and prognostic factors in patients undergoing
salvage therapy for recurrent esophagogastric cancer after
multimodal treatment.},
journal = {Journal of cancer research and clinical oncology},
volume = {149},
number = {4},
issn = {0171-5216},
address = {Berlin},
publisher = {Springer},
reportid = {DKFZ-2022-00752},
pages = {1373-1382},
year = {2023},
note = {#LA:D120# / 2023 Apr;149(4):1373-1382},
abstract = {Perioperative systemic treatment has significantly improved
the outcome in locally advanced esophagogastric cancer.
However, still the majority of patients relapse and die.
Data on the optimal treatment after relapse are limited, and
clinical and biological prognostic factors are
lacking.Patients with a relapse after
neoadjuvant/perioperative treatment and surgery for
esophagogastric cancer were analyzed using a prospective
database. Applied treatment regimens, clinical prognostic
factors and biomarkers were analyzed.Of 246 patients 119
relapsed. Among patients with a relapse event, those with an
early relapse (< 6 months) had an inferior overall survival
(OS 6.3 vs. 13.8 months, p < 0.001) after relapse than those
with a late relapse (> 6 months). OS after relapse was
longer in patients with a microsatellite-unstable (MSI)
tumor. Systemic treatment was initiated in 87 patients
$(73\%$ of relapsed pat.); among those OS from the start of
first-line treatment was inferior in patients with an early
relapse with 6.9 vs. 10.0 months (p = 0.037). In 27 patients
$(23\%$ of relapsed pat.), local therapy (irradiation or
surgical intervention) was performed due to oligometastatic
relapse, resulting in a prolonged OS in comparison to
patients without local therapy (median OS 35.2 months vs.
7.8 months, p < 0.0001). Multivariate analysis confirmed the
prognostic benefit of the MSI status and a local
intervention.Patients relapsing after multimodal treatment
have a heterogeneous prognosis depending on the relapse-free
interval (if systemic treatment applied), extent of
metastatic disease as well as MSI status. The benefit of
additional local intervention after relapse should be
addressed in a randomized trial.},
keywords = {Esophagogastric cancer (Other) / MSI (Other) /
Perioperative treatment (Other) / Relapse (Other) / Salvage
treatment (Other)},
cin = {F210 / D120},
ddc = {610},
cid = {I:(DE-He78)F210-20160331 / I:(DE-He78)D120-20160331},
pnm = {314 - Immunologie und Krebs (POF4-314)},
pid = {G:(DE-HGF)POF4-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:35441345},
doi = {10.1007/s00432-022-04016-y},
url = {https://inrepo02.dkfz.de/record/179574},
}